Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from New Ray Medicine International Holding Ltd. ( (HK:6108) ).
New Ray Medicine International Holding Ltd. announced supplemental information to its 2024 annual report, highlighting its investment in Shengzhou Xin Rui Wan Ma, which represents 5.9% of the Group’s total assets. This investment is held through a 39% stake in New Ray Wanma, the ultimate holding company of Shengzhou Xin Rui Wan Ma, indicating a strategic focus on maintaining significant investments in key pharmaceutical ventures.
More about New Ray Medicine International Holding Ltd.
New Ray Medicine International Holding Ltd. is a company incorporated in Bermuda with limited liability, primarily engaged in the pharmaceutical industry. The company, along with its subsidiaries, focuses on investments and holdings in various pharmaceutical ventures.
Average Trading Volume: 277,601
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$63.53M
See more insights into 6108 stock on TipRanks’ Stock Analysis page.